U.S. markets close in 3 hours 41 minutes
  • S&P 500

    4,289.81
    +9.66 (+0.23%)
     
  • Dow 30

    33,874.54
    +113.49 (+0.34%)
     
  • Nasdaq

    13,097.48
    +50.29 (+0.39%)
     
  • Russell 2000

    2,012.77
    -3.84 (-0.19%)
     
  • Crude Oil

    88.61
    -3.48 (-3.78%)
     
  • Gold

    1,794.50
    -21.00 (-1.16%)
     
  • Silver

    20.25
    -0.45 (-2.16%)
     
  • EUR/USD

    1.0177
    -0.0080 (-0.78%)
     
  • 10-Yr Bond

    2.7840
    -0.0650 (-2.28%)
     
  • GBP/USD

    1.2070
    -0.0069 (-0.57%)
     
  • USD/JPY

    133.2580
    -0.2220 (-0.17%)
     
  • BTC-USD

    24,230.07
    -281.90 (-1.15%)
     
  • CMC Crypto 200

    575.78
    -14.99 (-2.54%)
     
  • FTSE 100

    7,509.15
    +8.26 (+0.11%)
     
  • Nikkei 225

    28,871.78
    +324.80 (+1.14%)
     

Why Acutus Medical Shares Are Rallying Today?

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Acutus Medical Inc (NASDAQ: AFIB) has launched an expanded suite of left-heart access products, including the AcQCross Qx system for use with the TruSeal and FXD delivery system for the Watchman LAAC Device.

  • AcQCross is a transseptal system engineered with an integrated needle and dilator to reduce the multiple exchanges of wires and needles while trying to achieve the proper angle and location on the septum.

  • Related: Acutus Medical Stock Soars On Debt Refinancing, Divestiture Of Left-Heart Access Portfolio.

  • With this clearance, Acutus now offers sheath-compatible transseptal access devices covering 409,000 electrophysiology and structural heart procedures in the U.S.

  • Acutus Medical is an arrhythmia management company focused on improving how cardiac arrhythmias are diagnosed and treated.

  • Price Action: AFIB shares are up 104.31% at $1.10 during the premarket session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.